母体血液生物新标志物在唐氏综合征产前诊断效果及对预后的影响研究  

The effect of the new maternal blood biomarker on the prenatal diagnosis of Down syndrome and its effect on the prognosis

作　　者：付莲莲 FU Lian-lian(Tianjing City Jinghai Distract Hospital,Depart.Laborat,Tianjing Medical University,Tinghai Clinical College,301600)

机构地区：[1]天津市静海区医院检验科,天津医科大学静海临床学院,天津301600

出　　处：《中国优生与遗传杂志》2018年第7期60-62,共3页Chinese Journal of Birth Health & Heredity

摘　　要：目的探讨母体血液生物新标志物在唐氏综合征产前诊断效果及对预后的影响研究。方法回顾分析2016年5月-2017年5月我院收治的唐氏综合征患者80例,将其按随机数字法分为对照组和研究组,对照组应用常规CT扫描进行诊断,研究组应用母体血液生物新标志物进行诊断,观察两组患者的临床诊断符合率以及对患者预后的影响。结果临床诊断结果方面,研究组患者应用母体血液生物新标志物的临床诊断符合率明显高于对照组患者(P<0.05);研究组患者甲胎蛋白(AFP)、游离雌三醇(uE3)、游离人绒毛促性腺激素β亚单位(Freeβ-HCG)指标水平明显低于正常水平,研究组患者抑制素A的水平明显高于正常水平(P<0.05);预后影响方面,在干预前,两组患者的不良妊娠结局风险率无明显差别,在干预后,研究组患者不良妊娠结局风险率明显低于对照组患者(P<0.05)。结论在对唐氏综合征患者的诊断过程中,应用母体血液生物新标志物的诊断方法,可以提高患者的临床诊断符合率,降低患者不良妊娠的发生率,从而减少对孕妇生命健康带来的危害,临床上应当进一步推广应用。Objective：To investigate the effect of the new maternal blood biomarker on the prenatal diagnosis of Down syndrome and the effect on the prognosis. Methods：Retrospective analysis of May 2016-2017 year in May in our hospital 80 cases of patients with Down syndrome,which were randomly divided into control group and study group,the control group used conventional CT scanning for diagnosis,diagnosis of maternal blood group with new biological markers,observe two groups of patients with clinical diagnosis and the coincidence rate the effect on the prognosis of patients. Results：The clinical diagnosis results,was significantly higher than that of control group were consistent with the clinical diagnosis of maternal blood group of patients with new biological markers（P〈0.05）;patients in the study group of alpha fetoprotein（AFP）,free three female alcohol（uE3）,free human chorionic gonadotropin beta subunit（F beta-HCG）the index was significantly lower than the control group,patients in the study group,the level of inhibin A was significantly higher than the control group（P〈0.05）;prognosis,before intervention,the risk of adverse pregnancy outcomes of the two groups of patients there was no obvious difference in the intervention,the study group patients with the risk of adverse pregnancy outcomes was significantly lower than the control group patients（P〈0.05）. Conclusion：In the diagnosis of patients with Down syndrome,diagnosis methods of maternal blood biological markers,can improve the clinical diagnosis of patients,reduce the incidence of adverse pregnancy patients,thereby reducing the harm to life and health of pregnant women,should be further popularized in clinic.

关 键 词：母体血液生物新标志物 唐氏综合征 诊断效果 预后影响 

分 类 号：R714.55[医药卫生—妇产科学]